Home LiteratureArticle Details
PMID: 19156131 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data.

Molecular systems biology ·Vol. 5 ·2009-00-00 ·Pages 239

Chen WW, Schoeberl B, Jasper PJ, Niepel M, Nielsen UB, Lauffenburger DA, Sorger PK

Abstract

The ErbB signaling pathways, which regulate diverse physiological responses such as cell survival, proliferation and motility, have been subjected to extensive molecular analysis. Nonetheless, it remains poorly understood how different ligands induce different responses and how this is affected by oncogenic mutations. To quantify signal flow through ErbB-activated pathways we have constructed, trained and analyzed a mass action model of immediate-early signaling involving ErbB1-4 receptors (EGFR, HER2/Neu2, ErbB3 and ErbB4), and the MAPK and PI3K/Akt cascades. We find that parameter sensitivity is strongly dependent on the feature (e.g. ERK or Akt activation) or condition (e.g. EGF or heregulin stimulation) under examination and that this context dependence is informative with respect to mechanisms of signal propagation. Modeling predicts log-linear amplification so that significant ERK and Akt activation is observed at ligand concentrations far below the K(d) for receptor binding. However, MAPK and Akt modules isolated from the ErbB model continue to exhibit switch-like responses. Thus, key system-wide features of ErbB signaling arise from nonlinear interaction among signaling elements, the properties of which appear quite different in context and in isolation.

MeSH Terms
Kinetics MAP Kinase Signaling System Oncogene Proteins v-erbB/metabolism Sensitivity and Specificity Signal Transduction
Chemicals
Oncogene Proteins v-erbB
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Chen William W
Department of Systems Biology, Center for Cell Decision Processes, Harvard Medical School, Boston, MA 02115, USA.
Schoeberl Birgit
Jasper Paul J
Niepel Mario
Nielsen Ulrik B
Lauffenburger Douglas A
Sorger Peter K
References (67)
67 references, click to expand
  1. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors.
    Nat Biotechnol. 2002 Apr;20(4):370-5 PMID: 11923843
  2. Rotational dynamics of the epidermal growth factor receptor.
    Biochemistry. 2002 Feb 12;41(6):1957-64 PMID: 11827542
  3. Topology and robustness in the Drosophila segment polarity network.
    PLoS Biol. 2004 Jun;2(6):e123 PMID: 15208707
  4. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
    Cancer Res. 2004 Oct 15;64(20):7241-4 PMID: 15492241
  5. Prediction and validation of the distinct dynamics of transient and sustained ERK activation.
    Nat Cell Biol. 2005 Apr;7(4):365-73 PMID: 15793571
  6. The erbB3 gene product is a receptor for heregulin.
    J Biol Chem. 1994 May 13;269(19):14303-6 PMID: 8188716
  7. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.
    Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4995-5000 PMID: 10220407
  8. Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses.
    Mol Syst Biol. 2007;3:144 PMID: 18004277
  9. A module of negative feedback regulators defines growth factor signaling.
    Nat Genet. 2007 Apr;39(4):503-12 PMID: 17322878
  10. A rate equation approach to elucidate the kinetics and robustness of the TGF-beta pathway.
    Biophys J. 2006 Dec 15;91(12):4368-80 PMID: 17012329
  11. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.
    Cancer Res. 2006 Aug 15;66(16):8163-71 PMID: 16912195
  12. Phosphotyrosine interactome of the ErbB-receptor kinase family.
    Mol Syst Biol. 2005;1:2005.0008 PMID: 16729043
  13. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
    Science. 1987 Jan 9;235(4785):177-82 PMID: 3798106
  14. An integrated model of epidermal growth factor receptor trafficking and signal transduction.
    Biophys J. 2003 Aug;85(2):730-43 PMID: 12885624
  15. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells.
    Cell. 1992 Apr 3;69(1):205-16 PMID: 1348215
  16. The complexity of complexes in signal transduction.
    Biotechnol Bioeng. 2003 Dec 30;84(7):783-94 PMID: 14708119
  17. Universally sloppy parameter sensitivities in systems biology models.
    PLoS Comput Biol. 2007 Oct;3(10):1871-78 PMID: 17922568
  18. Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis.
    J Cell Biol. 2004 Sep 13;166(6):839-51 PMID: 15364960
  19. Protein phosphatase 2A forms a molecular complex with Shc and regulates Shc tyrosine phosphorylation and downstream mitogenic signaling.
    Mol Cell Biol. 2002 Apr;22(7):2375-87 PMID: 11884620
  20. Optimization by simulated annealing.
    Science. 1983 May 13;220(4598):671-80 PMID: 17813860
  21. A quantitative protein interaction network for the ErbB receptors using protein microarrays.
    Nature. 2006 Jan 12;439(7073):168-74 PMID: 16273093
  22. Differential algebra methods for the study of the structural identifiability of rational function state-space models in the biosciences.
    Math Biosci. 2001 Nov;174(1):1-26 PMID: 11595254
  23. Untangling the ErbB signalling network.
    Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 PMID: 11252954
  24. Ultrasensitivity in biochemical systems controlled by covalent modification. Interplay between zero-order and multistep effects.
    J Biol Chem. 1984 Dec 10;259(23):14441-7 PMID: 6501300
  25. Bayesian ranking of biochemical system models.
    Bioinformatics. 2008 Mar 15;24(6):833-9 PMID: 18057018
  26. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Mol Cancer Ther. 2004 Apr;3(4):465-72 PMID: 15078990
  27. EGF-ERBB signalling: towards the systems level.
    Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 PMID: 16829981
  28. Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1.
    Mol Cell Biol. 2007 Mar;27(6):2180-8 PMID: 17210635
  29. The structural identifiability and parameter estimation of a multispecies model for the transmission of mastitis in dairy cows.
    Math Biosci. 2001 Dec;174(2):77-90 PMID: 11730858
  30. Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells.
    J Biol Chem. 2005 Feb 18;280(7):6157-69 PMID: 15572377
  31. Why do protein kinase cascades have more than one level?
    Trends Biochem Sci. 1997 Aug;22(8):288 PMID: 9270298
  32. SH2 domains exhibit high-affinity binding to tyrosine-phosphorylated peptides yet also exhibit rapid dissociation and exchange.
    Mol Cell Biol. 1993 Mar;13(3):1449-55 PMID: 7680095
  33. Global dynamic optimization for parameter estimation in chemical kinetics.
    J Phys Chem A. 2006 Jan 26;110(3):971-6 PMID: 16419997
  34. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels.
    J Biol Chem. 2003 Jun 27;278(26):23343-51 PMID: 12686539
  35. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
    Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8132-6 PMID: 8058768
  36. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.
    Cancer Res. 1993 May 15;53(10 Suppl):2379-85 PMID: 7683573
  37. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
    Science. 2004 Aug 20;305(5687):1163-7 PMID: 15284455
  38. Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation.
    J Cell Biol. 1995 Jun;129(6):1543-58 PMID: 7790353
  39. Dynamic modelling and analysis of biochemical networks: mechanism-based models and model-based experiments.
    Brief Bioinform. 2006 Dec;7(4):364-74 PMID: 17107967
  40. Statistical mechanical approaches to models with many poorly known parameters.
    Phys Rev E Stat Nonlin Soft Matter Phys. 2003 Aug;68(2 Pt 1):021904 PMID: 14525003
  41. Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits.
    Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4221-6 PMID: 11904383
  42. A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling.
    Biochem J. 2003 Jul 15;373(Pt 2):451-63 PMID: 12691603
  43. Data-based identifiability analysis of non-linear dynamical models.
    Bioinformatics. 2007 Oct 1;23(19):2612-8 PMID: 17660526
  44. Ultrasensitivity in the mitogen-activated protein kinase cascade.
    Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10078-83 PMID: 8816754
  45. A hybrid approach for efficient and robust parameter estimation in biochemical pathways.
    Biosystems. 2006 Feb-Mar;83(2-3):248-65 PMID: 16236429
  46. Kinetics of protein-protein association explained by Brownian dynamics computer simulation.
    Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3338-42 PMID: 1565624
  47. Heregulin reverses the oligomerization of HER3.
    Biochemistry. 2000 Jul 25;39(29):8503-11 PMID: 10913256
  48. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
    Science. 2004 Jun 4;304(5676):1497-500 PMID: 15118125
  49. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
    EMBO J. 1997 Apr 1;16(7):1647-55 PMID: 9130710
  50. Reaction kinetics in intracellular environments with macromolecular crowding: simulations and rate laws.
    Prog Biophys Mol Biol. 2004 Jun-Jul;85(2-3):235-60 PMID: 15142746
  51. BioNetGen: software for rule-based modeling of signal transduction based on the interactions of molecular domains.
    Bioinformatics. 2004 Nov 22;20(17):3289-91 PMID: 15217809
  52. Three classes of epidermal growth factor receptors on HeLa cells.
    J Biol Chem. 1991 Jan 15;266(2):922-7 PMID: 1985972
  53. Sensitivity analysis of intracellular signaling pathway kinetics predicts targets for stem cell fate control.
    PLoS Comput Biol. 2007 Jul;3(7):e130 PMID: 17616983
  54. Parameter estimation using Simulated Annealing for S-system models of biochemical networks.
    Bioinformatics. 2007 Feb 15;23(4):480-6 PMID: 17038344
  55. Modular cell biology: retroactivity and insulation.
    Mol Syst Biol. 2008;4:161 PMID: 18277378
  56. Robustness as a measure of plausibility in models of biochemical networks.
    J Theor Biol. 2002 May 7;216(1):19-30 PMID: 12076125
  57. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
    Science. 2007 May 18;316(5827):1039-43 PMID: 17463250
  58. Mathematical models of protein kinase signal transduction.
    Mol Cell. 2002 May;9(5):957-70 PMID: 12049733
  59. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    N Engl J Med. 2001 Mar 15;344(11):783-92 PMID: 11248153
  60. Quantitative analysis of Grb2-Sos1 interaction: the N-terminal SH3 domain of Grb2 mediates affinity.
    Oncogene. 1995 Sep 21;11(6):1107-12 PMID: 7566970
  61. Quantification of short term signaling by the epidermal growth factor receptor.
    J Biol Chem. 1999 Oct 15;274(42):30169-81 PMID: 10514507
  62. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
    Cancer Cell. 2007 Mar;11(3):217-27 PMID: 17349580
  63. Ensemble modeling for analysis of cell signaling dynamics.
    Nat Biotechnol. 2007 Sep;25(9):1001-6 PMID: 17846631
  64. The segment polarity network is a robust developmental module.
    Nature. 2000 Jul 13;406(6792):188-92 PMID: 10910359
  65. Physicochemical modelling of cell signalling pathways.
    Nat Cell Biol. 2006 Nov;8(11):1195-203 PMID: 17060902
  66. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.
    Cancer Res. 2007 Mar 1;67(5):2325-30 PMID: 17332364
  67. The biochemical basis of an all-or-none cell fate switch in Xenopus oocytes.
    Science. 1998 May 8;280(5365):895-8 PMID: 9572732
Article Info
Journal
Molecular systems biology
Abbr.
Mol Syst Biol
ISSN
1744-4292
Published
2009-00-00
Epub
2009-00-20
Pages
239
Language
English
Region
England
NLM ID
101235389
PMCID
PMC2644173
Subset
IM
Grants
NIGMS NIH HHS · P50 GM068762 · United States
NCI NIH HHS · U54 CA112967 · United States
NIGMS NIH HHS · GM68762 · United States
NCI NIH HHS · CA112967 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]